氟化NP-59的研制:胆固醇利用显像在PET中的复兴
本研究制备了NP-59的18F类似物18F-FNP-59,用于基于胆固醇利用的肾上腺PET功能显像。临床前研究显示其药代动力学与NP-59相似但辐射暴露降低,动物显像可见胆囊、肝脏和肾上腺摄取;首次人体研究受试者无不良事件,图像显示肝脏和肾上腺靶组织聚集,给予促肾上腺皮质激素后摄取改善。
要点
- 18F-FNP-59在小鼠毒性研究中于预期剂量下安全,动物显像可见胆固醇利用组织(胆囊、肝脏、肾上腺)摄取。
- 首次人体研究中受试者无不良事件,图像显示肝脏和肾上腺靶组织聚集,给予促肾上腺皮质激素后摄取改善。
- 18F-FNP-59提供更高分辨率图像且受试者辐射剂量更低,作者认为其有潜力为肾上腺皮质疾病患者提供无创检查。
核心结论
- 18F-FNP-59提供更高分辨率的图像,且对受试者的辐射剂量更低,作者认为其有潜力为肾上腺皮质疾病患者提供无创检查。
研究设计与样本
- 研究制备了NP-59的18F类似物18F-FNP-59,描述了其放射化学,并在啮齿动物中进行了辐射剂量学研究和在新西兰兔中进行了体内显像。
- 在体内毒性研究后获得研究性新药批准,并采集了首例人体图像及该药物的剂量学数据。
主要发现
- 体内毒性研究表明FNP-59在预期剂量下使用是安全的。
- 18F-FNP-59的生物分布研究显示其药代动力学特征与NP-59相似,但辐射暴露降低。
- 动物体内图像显示在利用胆固醇的组织(胆囊、肝脏和肾上腺)中出现预期摄取。
- 在首次人体研究中,受试者无不良事件,图像显示在靶组织(肝脏和肾上腺)中聚集。
- 在接受促肾上腺皮质激素的患者中证实了摄取可被调控,导致摄取改善。
临床怎么用
- 作者认为18F-FNP-59有潜力为肾上腺皮质疾病患者提供无创检查。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Imaging of cholesterol use is possible with the 131I scintiscanning/SPECT agent NP-59. This agent provided a noninvasive measure of adrenal function and steroid synthesis. However, iodine isotopes resulted in poor resolution, manufacturing challenges, and high radiation dosimetry to patients that have limited their use and clinical impact. A 18F analog would address these shortcomings while retaining the ability to image cholesterol use. The goal of this study was to prepare and evaluate a 18F analog of NP-59 to serve as a PET imaging agent for functional imaging of the adrenal glands based on cholesterol use. Previous attempts to prepare such an analog of NP-59 have proven elusive. Preclinical and clinical evaluation could be performed once the new fluorine analog of NP-59 production was established. Methods: The recent development of a new reagent for fluorination along with an improved route to the NP-59 precursor allowed for the preparation of a fluorine analog of NP-59, FNP-59. The radiochemistry for the 18F-radiolabeled 18F-FNP-59 is described, and rodent radiation dosimetry studies and in vivo imaging in New Zealand rabbits was performed. After in vivo toxicity studies, an investigational new drug approval was obtained, and the first-in-humans images with dosimetry using the agent were acquired. Results: In vivo toxicity studies demonstrated that FNP-59 is safe for use at the intended dose. Biodistribution studies with 18F-FNP-59 demonstrated a pharmacokinetic profile similar to that of NP-59 but with decreased radiation exposure. In vivo animal images demonstrated expected uptake in tissues that use cholesterol: gallbladder, liver, and adrenal glands. In this first-in-humans study, subjects had no adverse events and images demonstrated accumulation in target tissues (liver and adrenal glands). Manipulation of uptake was also demonstrated with patients who received cosyntropin, resulting in improved uptake. Conclusion: 18F-FNP-59 provided higher resolution images, with lower radiation dose to the subjects. It has the potential to provide a noninvasive test for patients with adrenocortical diseases.
引用
- Brooks AF, Winton WP, Stauff J, et al. Development of Fluorinated NP-59: A Revival of Cholesterol Use Imaging with PET. J Nucl Med. 2022. PMID: 35483964. doi:10.2967/jnumed.122.263864
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。